{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1362825895033525248.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1007/s00210-006-0080-3"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/content/pdf/10.1007/s00210-006-0080-3.pdf"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/article/10.1007/s00210-006-0080-3/fulltext.html"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/content/pdf/10.1007/s00210-006-0080-3"}}],"dc:title":[{"@value":"Metabolic effects of antihypertensive agents: role of sympathoadrenal and renin-angiotensin systems"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1382825895033525376","@type":"Researcher","foaf:name":[{"@value":"Paul Ernsberger"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895033525377","@type":"Researcher","foaf:name":[{"@value":"Richard J. Koletsky"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00281298"},{"@type":"EISSN","@value":"14321912"}],"prism:publicationName":[{"@value":"Naunyn-Schmiedeberg's Archives of Pharmacology"}],"dc:publisher":[{"@value":"Springer Science and Business Media LLC"}],"prism:publicationDate":"2006-06-17","prism:volume":"373","prism:number":"4","prism:startingPage":"245","prism:endingPage":"258"},"reviewed":"false","dc:rights":["http://www.springer.com/tdm"],"url":[{"@id":"http://link.springer.com/content/pdf/10.1007/s00210-006-0080-3.pdf"},{"@id":"http://link.springer.com/article/10.1007/s00210-006-0080-3/fulltext.html"},{"@id":"http://link.springer.com/content/pdf/10.1007/s00210-006-0080-3"}],"createdAt":"2006-06-16","modifiedAt":"2025-01-09","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/2051151842055064064","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Hydrochlorothiazide ameliorates polyuria caused by tolvaptan treatment of polycystic kidney disease in PCK rats"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1007/s00210-006-0080-3"},{"@type":"CROSSREF","@value":"10.1007/s10157-018-1669-9_references_DOI_3MSlvbtKOTBzOmb0K2qk8cezM2P"}]}